MedTrace Logo

Effect Of Ezetimibe Coadministration With Simvastatin In A Middle Eastern Population: A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial (0653-151)

NCT00652444 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2022-02-18

No results posted yet for this study

Summary

The primary outcome was percentage reduction of LDL-C after 6 weeks of randomization.

Conditions

Interventions

DRUG

ezetimibe

ezetimibe 10mg. Blood samples were collected again at the end of study treatment, week 6.

DRUG

simvastatin

simvastatin 20mg . Blood samples were collected again at the end of study treatment, week 6.

DRUG

Placebo (Unspecified)

Matching ezetimibe placebo

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2004-08-31
Completion
2004-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00652444 on ClinicalTrials.gov